8-A842A-2018-Multiple-00021-Chapter 29-ROUND1

567

Chapter 29 Chemical Modifiers of Radiation Response

54. Overgaard J, Overgaard M, Nielsen OS, et al. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br J Cancer 1982;46(6):904–911. 55. Overgaard J, Hansen HS, Overgaard M, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998;46(2):135–146. 56. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluoro- uracil and radiotherapy, and of salvage chemoradiation in the definitive nonsur- gical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996;14(9):2527–2539. 57. Haffty BG, Son YH, Papac R, et al. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale mitomycin randomized trials. J Clin Oncol 1997;15(1):268–276. 58. Dobrowsky W, Naude J. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. Radiother Oncol 2000;57(2): 119–124. 59. Rockwell S, Hughes CS. Effects of mitomycin C and porfiromycin on exponen- tially growing and plateau phase cultures. Cell Prolif 1994;27(3):153–163. 60. Haffty BG, Wilson LD, Son YH, et al. Concurrent chemo-radiotherapy withmitomy- cin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial. Int J Radiat Oncol Biol Phys 2005;61(1): 119–128. 61. Zeman EM, Brown JM, Lemmon MJ, et al. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 1986;12(7):1239–1242. 62. Zeman EM, Hirst VK, Lemmon MJ, et al. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. Radiother Oncol 1988;12(3): 209–218. 63. Zeman EM, Brown JM. Pre- and post-irradiation radiosensitization by SR 4233. Int J Radiat Oncol Biol Phys 1989;16(4):967–971. 64. Brown JM, Lemmon MJ. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 1990;50(24):7745–7749. 65. Brown JM, Lemmon MJ. SR 4233: a tumor specific radiosensitizer active in frac- tionated radiation regimes. Radiother Oncol 1991;20(Suppl 1):151–156. 66. Brown JM, Lemmon MJ. Tumor hypoxia can be exploited to preferentially sensi- tize tumors to fractionated irradiation. Int J Radiat Oncol Biol Phys 1991;20(3): 457–461. 67. Brown JM. Therapeutic targets in radiotherapy. Int J Radiat Oncol Biol Phys 2001; 49(2):319–326. 68. Goldberg Z, Evans J, Birrell G, et al. An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin. Int J Radiat Oncol Biol Phys 2001;49(1):175–182. 69. Rischin D, Peters L, Hicks R, et al. Phase I trial of concurrent tirapazamine, cis- platin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19(2):535–542. 70. Rischin D, Peters L, Fisher R, et al. Tirapazamine, cisplatin, and radiation ver- sus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 2005;23(1):79–87. 71. Rischin D, Hicks RJ, Fisher R, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006;24(13):2098–2104. 72. Rischin D, Peters LJ, O’Sullivan B, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010;28(18):2989–2995. 73. Peters LJ, O’Sullivan B, Giralt J, et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol 2010;28(18):2996–3001. 74. Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 2007;4(3):156–171. 75. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62(24):7350–7356. 76. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6(6): 2166–2174. 77. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999;59(8):1935–1940. 78. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth fac- tor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19(13):3234–3243. 79. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567–578. 80. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locore- gionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11(1):21–28. 81. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100(4):261–269. 82. Ang KK, Zhang QE, Rosenthal DI, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatinwith or without cetuximab for stage III–IV head and neck squamous cell carcinomas (HNC). ASCO Meet Abstr 2011; 29(15 Suppl):5500. 83. Yuhas JM, Spellman JM, Culo F. The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trial 1980;3(3):211–216. 84. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifos- tine as a radioprotector in head and neck cancer. J Clin Oncol 2000;18(19):3339– 3345. 85. Wasserman TH, Brizel DM, Henke M, et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys 2005;63(4):985–990.

86. Koukourakis MI, Kyrias G, Kakolyris S, et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 2000;18(11):2226–2233. 87. Boccia R, Anne PR, Bourhis J, et al. Assessment and management of cutane- ous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP). Int J Radiat Oncol Biol Phys 2004; 60(1):302–309. 88. Lindegaard JC, Grau C. Has the outlook improved for amifostine as a clinical radioprotector? Radiother Oncol 2000;57(2):113–118. 89. Simon R. Design and analysis of clinical trials. In: DeVita V, Lawrence T, Rosenberg S, eds. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott- Raven, 2008:571–590. 90. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48(1):7–16. 91. Bourhis J, Blanchard P, Maillard E, et al. Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data. J Clin Oncol 2011;29(18):2590–2597. 92. Movsas B, Scott C, Langer C, et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group trial 98-01. J Clin Oncol 2005;23(10):2145–2154. 93. Movsas B. Exploring the role of the radioprotector amifostine in locally advanced non-small cell lung cancer: Radiation Therapy Oncology Group trial 98-01. Semin Radiat Oncol 2002;12(1 Suppl 1):40–45. 94. Vujaskovic Z, Feng QF, Rabbani ZN, et al. Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity. Exp Lung Res 2002; 28(7):577–590. 95. Vujaskovic Z, Feng QF, Rabbani ZN, et al. Radioprotection of lungs by amifostine is associated with reduction in profibrogenic cytokine activity. Radiat Res 2002; 157(6):656–660. 96. Vujaskovic Z, Thrasher BA, Jackson IL, et al. Radioprotective effects of amifos- tine on acute and chronic esophageal injury in rodents. Int J Radiat Oncol Biol Phys 2007;69(2):534–540. 97. Antonadou D, Pepelassi M, Synodinou M, et al. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and- neck cancer. Int J Radiat Oncol Biol Phys 2002;52(3):739–747. 98. Buntzel J, Glatzel M, Kuttner K, et al. Amifostine in simultaneous radiochemother- apy of advanced head and neck cancer. Semin Radiat Oncol 2002;12(1 Suppl 1): 4–13. 99. Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011;12(2):127–136. 100. Thorstad WL, Chao KS, Haughey B. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer. Semin Oncol 2004;31(6 Suppl 18):8–12. 101. Potten CS, O’Shea JA, Farrell CL, et al. The effects of repeated doses of keratino- cyte growth factor on cell proliferation in the cellular hierarchy of the crypts of the murine small intestine. Cell Growth Differ 2001;12(5):265–275. 102. Dorr W, Spekl K, Farrell CL. Amelioration of acute oral mucositis by keratino- cyte growth factor: fractionated irradiation. Int J Radiat Oncol Biol Phys 2002; 54(1):245–251. 103. Dorr W, Spekl K, Farrell CL. The effect of keratinocyte growth factor on healing of manifest radiation ulcers inmouse tongue epithelium. Cell Prolif 2002;35(Suppl 1): 86–92. 104. Chen L, Brizel DM, Rabbani ZN, et al. The protective effect of recombinant human keratinocyte growth factor on radiation-induced pulmonary toxicity in rats. Int J Radiat Oncol Biol Phys 2004;60(5):1520–1529. 105. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after inten- sive therapy for hematologic cancers. N Engl J Med 2004;351(25):2590–2598. 106. Brizel DM, Murphy BA, Rosenthal DI, et al. Phase II study of palifermin and con- current chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol 2008;26(15):2489–2496. 107. Le QT, Kim HE, Schneider CJ, et al. Palifermin reduces severe mucositis in defini- tive chemoradiotherapy of locally advanced head and neck cancer: a random- ized, placebo-controlled study. J Clin Oncol 2011;29(20):2808–2814. 108. Henke M, Alfonsi M, Foa P, et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. J Clin Oncol 2011;29(20):2815–2820. 109. Martin F, Farley A, Gagnon M, et al. Comparison of the healing capacities of sucralfate and cimetidine in the short-term treatment of duodenal ulcer: a double-blind randomized trial. Gastroenterology 1982;82(3):401–405. 110. Makkonen TA, Bostrom P, Vilja P, et al. Sucralfate mouth washing in the preven- tion of radiation-induced mucositis: a placebo-controlled double-blind random- ized study. Int J Radiat Oncol Biol Phys 1994;30(1):177–182. 111. Meredith R, Salter M, Kim R, et al. Sucralfate for radiation mucositis: results of a double-blind randomized trial. Int J Radiat Oncol Biol Phys 1997;37(2):275–279. 112. Pfeiffer P, Madsen EL, Hansen O, et al. Effect of prophylactic sucralfate suspen- sion on stomatitis induced by cancer chemotherapy. A randomized, double-blind cross-over study. Acta Oncol 1990;29(2):171–173. 113. Segre G, Hammarstrom S. Aspects of the mechanisms of action of benzydamine. Int J Tissue React 1985;7(3):187–193. 114. Sironi M, Pozzi P, Polentarutti N, et al. Inhibition of inflammatory cytokine produc- tion and protection against endotoxin toxicity by benzydamine. Cytokine 1996; 8(9):710–716. 115. Epstein JB, Silverman S Jr, Paggiarino DA, et al. Benzydamine HCl for prophy- laxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 2001;92(4):875–885. 116. Bellm L, Lehrer RI, Ganz T. Protegrins: new antibiotics of mammalian origin. Expert Opin Investig Drugs 2000;9(8):1731–1742. 117. Giles FJ, Miller CB, Hurd DD, et al. A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial). Leuk Lymphoma 2003;44(7):1165–1172. 118. Trotti A, Garden A, Warde P, et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys 2004;58(3):674–681.

Techniques, Modalities, and Modifiers in Radiation Oncology